Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

What is the purpose of this trial?

A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo


Participation Guidelines

Ages: 10 - 24 years

Gender: Both


Astra Zeneca, L.P.

Dates: 08/29/2016 - 07/31/2019

Last Updated: 09/02/2016

Study HIC#: 1603017459

Get Involved

For more information about this study, contact:
Amy Steffen
+1 203-737-8852
amy.steffen@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

William V Tamborlane

Principal Investigator

Sub-Investigators